Cargando…

P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects

Rimegepant (Nurtec ODT)—an orally administered, small‐molecule calcitonin gene–related peptide receptor antagonist indicated for the acute and preventive treatment of migraine—is a substrate for both the P‐glycoprotein and breast cancer resistance protein transporters in vitro. We evaluated the effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhardwaj, Rajinder, Collins, Julie L., Stringfellow, Joseph, Madonia, Jennifer, Anderson, Matt S., Finley, Jeri‐anne, Stock, David A., Coric, Vladimir, Croop, Robert, Bertz, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311059/ https://www.ncbi.nlm.nih.gov/pubmed/35304977 http://dx.doi.org/10.1002/cpdd.1088

Ejemplares similares

Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women
por: Baker, Teresa E., et al.
Publicado: (2022)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
por: Johnston, Karissa M., et al.
Publicado: (2021)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
por: Powell, Lauren C., et al.
Publicado: (2022)

Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial
por: Croop, Robert, et al.
Publicado: (2022)

Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats
por: Wang, Qiong, et al.
Publicado: (2019)

The Price of Quinidine
Publicado: (1922)

Antagonism of CGRP Signaling by Rimegepant at Two Receptors
por: Pan, Kylie S., et al.
Publicado: (2020)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
por: Johnston, Karissa, et al.
Publicado: (2022)

Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
por: Blair, Hannah A.
Publicado: (2023)

Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
por: Blair, Hannah A.
Publicado: (2023)

Alteration in P-glycoprotein Functionality Affects Intrabrain Distribution of Quinidine More Than Brain Entry—A Study in Rats Subjected to Status Epilepticus by Kainate
por: Syvänen, Stina, et al.
Publicado: (2012)

A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers
por: Pope, Laura E., et al.
Publicado: (2012)

Quinidine for Brugada syndrome: Panacea or poison?
por: Hai, Jo-Jo, et al.
Publicado: (2016)

Use of Rimegepant in the Management of Cervicogenic Headache Secondary to Trauma: A Case Series
por: Zaw, Shin T, et al.
Publicado: (2023)

The Therapeutic Value of Quinidine Sulphate in Auricular Fibrillation
por: Ritchie, W. T.
Publicado: (1922)

Deuterated dextromethorphan/quinidine for agitation in Alzheimer's disease
por: Khoury, Rita
Publicado: (2021)

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
por: Gao, Bixi, et al.
Publicado: (2020)

Action of quinidine on ionic currents of molluscan pacemaker neurons
Publicado: (1984)

Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia
por: Tampi, Rajesh R, et al.
Publicado: (2020)

Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials
por: Wang, Qinghui, et al.
Publicado: (2023)

An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects
por: Bifano, Marc, et al.
Publicado: (2015)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect
por: Schoedel, Kerri A, et al.
Publicado: (2014)

Observations on the Action of Quinidine Sulphate on Three Cases of Auricular Fibrillation
por: Walwyn, W. M'L., et al.
Publicado: (1922)

The case for quinidine: Management of electrical storm in refractory ventricular fibrillation
por: Pinnelas, Rebecca, et al.
Publicado: (2020)

Dextromethorphan/quinidine for the treatment of bulbar impairment in amyotrophic lateral sclerosis
por: Tabor Gray, Lauren, et al.
Publicado: (2023)

Is the right way to go in between?: Rimegepant as needed provides preventive benefit. A comment on: monthly migraine days, tablet utilization, and quality of life associated with rimegepant—post hoc results from an open label safety study (BHV3000–201)
por: Gantenbein, Andreas R., et al.
Publicado: (2023)

A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer.
por: Jones, R. D., et al.
Publicado: (1990)

Beneficial Effects of Isoproterenol and Quinidine in the Treatment of Ventricular Fibrillation in Brugada Syndrome
por: Dakkak, Melissa, et al.
Publicado: (2015)

Quinidine effective for the management of ventricular and atrial arrhythmias associated with Brugada syndrome
por: Halperin, Laura, et al.
Publicado: (2018)

Effects of Quinine, Quinidine and Chloroquine on Human Muscle Nicotinic Acetylcholine Receptors
por: Gisselmann, Günter, et al.
Publicado: (2018)

Electrical storm in an acquired short QT syndrome successfully treated with quinidine
por: Spartalis, Michael, et al.
Publicado: (2019)

Effects of Nigella sativa and Lepidium sativum on Cyclosporine Pharmacokinetics
por: Al-Jenoobi, F. I., et al.
Publicado: (2013)

Effects of intestinal microbiota on pharmacokinetics of cyclosporine a in rats
por: Zhou, Jinping, et al.
Publicado: (2022)

The Pharmacokinetic and Absolute Bioavailability of Cyclosporine (Atopica for Cats(®)) in Cats
por: Kong, Jingyuan, et al.
Publicado: (2023)

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
por: Mullin, Kathleen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5btj68bf4c5bl6qjoopcv2hiqg